Franklin Templeton Chairman Mark Mobius has opposed Sun Pharma's $454 million acquisition of Israel's Taro Pharmaceutical. |
In a filing with the Securities and Exchange Commission, Templeton, which holds a 9 per cent stake in Taro, said that Sun's offer of $7.75 a share is too low and unjust to the minority shareholders of Taro. |
|
In a letter to Taro, Mobius said the company should cancel the deal with Sun and reveal critical information regarding the financial status of the company to all its shareholders. |
|
Templeton also sought a temporary injunction in a Tel-Aviv district court to prevent Taro from entering into the transaction. |
|
It also filed a motion for the appointment of a special interim manager to review the company's efforts to identify an appropriate transaction. |
|
The court will hear the petition on September 19, two months after the Taro general shareholders' meeting to approve the deal, which will be held on July 23. |
|
It also alleged that Taro and its executives are acting in a way that is liable to drive the company into insolvency. |
|
Earlier, Brandes Investment Partners, the second-largest shareholder in Taro, had indicated that it plans to vote against the Sun acquisition. |
|